Daniel Krappmann

Prof. Dr. Daniel Krappmann is an Adjunct Professor at the Faculty of Biology, Ludwig-Maximilians-Universität München, with extensive leadership in research units at Helmholtz Munich and Max-Delbrück-Center (MDC) Berlin. His work bridges basic immunology and translational oncology, focusing on signaling pathways in immune activation and cancer.

• Director, Research Unit Signaling and Translation (2023–present)
• Head, Research Unit Cellular Signal Integration (2013–present)
• Adjunct Professor, Faculty of Biology, LMU Munich (2012–present)

Research Focus: Krappmann investigates molecular mechanisms of immune signaling, particularly the MALT1 protease, and translates these findings into therapies for cancer and immune disorders. His work includes drug discovery programs targeting aberrant signaling networks.

Publication Trends: His recent articles emphasize MALT1's role in T cell biology, immune dysregulation, and pharmacological inhibition strategies. Keywords span Immunology, Oncology, and Cell Signaling, with subfields like RNA processing, Protease inhibition, and Cancer immunology.

Scientific Awards

• Delbrück Fellowship Award (MDC Berlin, 2002)

Clinical Translation: Krappmann leads pre-clinical development of immune-modulatory drugs, including phenothiazine-based MALT1 inhibitors now in clinical trials for aggressive lymphomas. His work integrates academic research with therapeutic applications.

Networks & Affiliations: Collaborates with DFG SFB1335 (Aberrant Immune Signals in Cancer) and SFB 1054 (Cell-Fate Plasticity in Immunity), alongside his roles at Helmholtz Munich and LMU Munich.